Read More

Outset Medical Reports Unaudited Q4 And 2023 Revenue, Provides 2024 Revenue And Non-GAAP Gross Margin Guidance; Q4 Revenue Totaled $30.5M Vs $30.13M Est.; Sees FY23 Revenue $130M Vs $130.01M Est.; Sees FY24 Revenue $145M-$153M Vs $149.06M Est.

Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis,today reported unaudited revenue for the fourth quarter

OM

Read More

iRhythm Technologies Shares Preliminary Q4 2023 Highlights And Business Update At The 42nd Annual J.P. Morgan Healthcare Conference; Grew Q4 2023 Patient Registrations In Excess Of 22% YoY; Sees FY24 Revenue $575M-$585M Vs 578.72M Est.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational

IRTC

Read More

Corcept Therapeutics Provides Financial Update And Announces $200M Stock Repurchase Program; Sees Q4 Revenue $135.4M Vs $127.85M Est.; FY23 Revenue $482.4M Vs $474.82M Est.; FY24 Revenue $600M–$630M Vs $513.85M Est.

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating

CORT

Read More

Praxis Precision Medicines Provides Update On Advancing Clinical Stage Portfolio; Recently Announced Licensing Partnership With Tenacia Biotechnology To Develop And Commercialize Ulixacaltamide In Greater China With Total Consideration Over $275M

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg

IONS

Read More

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights For Q4 & FY23; Sees Q4 Revenue $37.6M Vs $37.77M Est.; FY23 Revenue $148.7M Vs $148.88M Est.; Sees FY24 Revenue $197M-$200M Vs $177.7M Est

OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth

KIDS